相关实验视频
Updated: Jun 5, 2025

06:47
A Murine Model of Vertical Sleeve Gastrectomy
Published on: December 18, 2017
11.1K
除了脂肪之外:塞马格卢提德是否会影响肌肉质量?
Tannaz Jamialahmadi1, Ali H Eid2, Kishore M Gadde3
1Pharmaceutical Research Center, Pharmaceutical Technology Institute, Mashhad University of Medical Sciences, Mashhad, Iran; Medical Toxicology Research Center, Mashhad University of Medical Sciences, Mashhad, Iran.
Clinical nutrition (Edinburgh, Scotland)
|December 8, 2024
概括
塞马格卢提德会导致显著的体重减轻,但它对瘦身质量的影响仍在争论中. 一些研究表明瘦肉质量损失,而另一些研究表明更高的瘦肉质量比率,需要进一步研究.
科学领域:
- 内分泌学 在内分泌学.
- 代谢研究研究 代谢研究
- 药理学 药理学是指药理学的学科.
背景情况:
- 赛马格卢提德是一种GLP-1RA,广泛用于减肥.
- 它对瘦身量以及脂肪量减少的影响是正在进行的科学讨论的主题.
研究的目的:
- 分析塞马格卢提德对瘦身质量的影响.
- 讨论围绕在西马格卢提德治疗期间瘦肉量变化的争议.
主要方法:
- 审查现有的临床试验和研究结果关于塞马格卢提德对身体组成的影响.
- 分析关于瘦肉质量和脂肪质量变化的相互矛盾数据.
主要成果:
- 随着塞马格卢提德的使用,人们一直观察到体重减轻.
- 研究对瘦肉质量提出了相互矛盾的结果:一些研究报告说瘦肉质量下降,而另一些研究则指出瘦肉质量增加到总体质量比.
- 较大的临床试验表明显著的瘦肉量减少.
结论:
- 由于矛盾的发现,塞马格卢提德对瘦肉质的净效应需要进一步调查.
- 额外的研究是至关重要的,鉴于越来越多的使用semaglutide的流行.
相关概念视频
Glucagon-like Receptor Agonists
298
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
298
Dipeptidyl Peptidase 4 Inhibitors
171
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
171
Oral Hypoglycemic Agents: Glinides
139
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
139
Insulin: Dosing Regimen and Adverse Effects
145
Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
145
Oral Hypoglycemic Agents: Biguanides and Glitazones
172
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
172
Disorders of the Skeletal Muscle
876
The clinical conditions affecting the skeletal muscle tissue are broadly categorized as musculoskeletal and neuromuscular disorders.
Musculoskeletal disorders
Musculoskeletal disorders involve injuries and conditions affecting the skeletal muscles and associated connective tissues. These disorders can arise from acute biomechanical stresses or chronic overuse and can occur across different age groups. Common injuries include sprains, fractures, and muscular strains, often resulting from...
Musculoskeletal disorders
Musculoskeletal disorders involve injuries and conditions affecting the skeletal muscles and associated connective tissues. These disorders can arise from acute biomechanical stresses or chronic overuse and can occur across different age groups. Common injuries include sprains, fractures, and muscular strains, often resulting from...
876

